03 · Client story
VMI Group
IP protection for what could be the world’s largest and most precise medication dispenser
At first glance, the VMI INDIVION is an impressive piece of engineering, yet its most important innovations are invisible. To create this giant medication dispensing system, VMI Group combined highly sophisticated machine engineering with intelligent software. The result is a machine capable of producing 10,000 personalised medication pouches per hour. Each pouch contains a different combination of medications, tailored to an individual prescription and clearly labelled for a specific patient. All this is achieved with an exceptionally low error rate and a minimal risk of cross-contamination or product damage, as VMI explains.
A global organisation with offices in 11 countries, VMI Group’s headquarters are located just outside Epe, near De Hoge Veluwe in the Dutch province of Gelderland. We meet Head of Pharma Engineering Patrick van Voorn and Director IP Gwen ten Berge, together with their patent attorney Catherine Shultz of NLO. The conversation centres on the development of the INDIVION and how the company protects the intellectual property behind it. But first, some background.
About VMI
VMI Group was founded in 1945, initially helping to support the Netherlands’ post-war reconstruction efforts. The company first focused on railway restoration before expanding into the manufacture of products including tyre-building machines and can washers. VMI’s goal is straightforward: to develop technology to help their customers become more successful. In 2015, the company expanded into the pharmaceutical sector with the launch of its Care Pharma division. It was a strategic move: an ageing population has created a growing market with significant potential, and VMI saw an opportunity to innovate in an area where automation could make a meaningful difference. That ultimately led the company to focus on improving the dispensing of medication.
“The INDIVION produces 10,000 pouches of prescribed medication every hour.”
Developing INDIVION
INDIVION was developed in response to a need identified by a Swedish customer, who identified that existing medication dispensing systems could no longer keep up with market demands. Medication was often damaged or contaminated during the packaging process, and highly qualified staff were required to operate the machines. Patrick explains: “The technology was already around 30 years old. Our goal was to develop a new system with a lower error rate that could package large volumes of prescribed medication quickly and efficiently, while requiring minimal human intervention. We wanted to create a machine that was ready for the challenges of tomorrow.”
A significantly lower error rate
Developing the INDIVION took a considerable amount of time. As one of the inventors behind the technology, Patrick explains what sets the machine apart: “The end product is a medication pouch for an individual patient. Every pouch is unique, with different printed information and different contents for each. The INDIVION produces 10,000 of those pouches every hour.” He highlights another significant improvement: “Older packaging systems had an error rate of 1 in 400. With INDIVION, this is reduced to 1 in 1,200. At one customer site, for example, final checks no longer require 12 pharmacists but just four employees. Those employees only need practical skills because they no longer have to make pharmaceutical decisions. As a result, our customer saves around €1 million a year.”
One million pouches a day
Patrick emphasises the importance of both the canisters and the software that controls INDIVION. Both are protected by patents. The canisters store different types of medication, while INDIVION controls how those medicines are dispensed according to individual prescriptions. “Imagine having around 1,000 different medications, all with different shapes and characteristics, that need to be combined correctly in a single pouch without being damaged or contaminating one another. On average, each pouch contains three tablets, so INDIVION dispenses around 30,000 tablets an hour without damage or cross-contamination. One of our customers now produces around one million individual pouches a day for more than 200,000 patients.”
Patent or trade secret?
Gwen explains that VMI evaluates each invention from a commercial, technical and IP standpoint before deciding whether it should be protected by patent, kept confidential or published. For the INDIVION patent portfolio, VMI chose to work with NLO “because of their international experience and broad expertise,” Gwen explains. “The pharmaceutical sector moves quickly. As a result, awareness of IP is much greater than in many of the markets we’re used to operating in. The sector is more heavily regulated and competition around IP is far more assertive. That requires a very different approach to IP strategy. The knowledge we’re building in this area is also proving valuable for our tyre division.”
“Catherine is both a European patent attorney and a US patent attorney.
That is essential for us.”
Bridging two worlds
Catherine is VMI’s regular patent attorney at NLO. Gwen had worked with her previously and values the strategic input she brings. “She has both a technical and legal background and as a result, she understands the INDIVION and the PHARYS software platform that forms part of it in remarkable detail. She helps me shape our IP strategy while also being able to discuss technical matters directly with Patrick, our lead inventor. At the same time, Catherine is both a European patent attorney and a US patent attorney. She bridges two worlds, which is essential for us because Europe and the United States are our most important markets.”
The importance of strong claims
Patrick stresses how important it is for inventors and patent attorneys to understand one another. “I explain how a machine works, but turning that into a patent application involves a lot more than simply writing it down. First, Catherine has to understand what I’m saying, identify what is genuinely novel and then translate that into effective patent language. Drafting the right claims is crucial. If something isn’t included, it isn’t protected. Whenever I discuss an invention with Catherine, she identifies claim opportunities I hadn’t considered myself.”
From two patent families to twenty
Catherine also supports VMI when discussions arise with patent examiners regarding the novelty of an invention. Patrick explains: “The key question is whether a solution truly doesn’t already exist. That requires specialist patent expertise, and Catherine has that expertise. She helped us secure patents that we wouldn’t have obtained with a patent attorney specialising solely in mechanical engineering.”
Catherine smiles before responding: “VMI’s robotics and packaging technologies are fantastic. That makes building IP protection around them a rewarding challenge. I think VMI Care Pharma had two patent families when I first became involved. Today, there are around twenty. It’s been exciting to see the business grow and evolve while building that portfolio together.”
Finding room to innovate
Patrick emphasises that, when patenting elements of INDIVION, VMI wanted to ensure it did not infringe the rights of other companies. “That’s why we carried out thorough research into existing inventions before we started.” Catherine continues: “In the pharmaceutical sector, companies invest heavily in building patent portfolios. VMI takes a principled approach and has no desire to infringe on valid intellectual property rights. So we did our homework together: we reviewed the existing patent landscape and looked carefully for opportunities to innovate without encroaching on someone else’s IP.”
Advice for inventors
VMI now has around 250 patent families and approximately 2,500 patent registrations worldwide. A further 20 to 30 patent families are added each year. With that level of experience around the table, we ask Gwen, Patrick and Catherine what advice they would give inventors with little or no IP experience. Patrick immediately replies: “Make sure your patent position is secure before you start talking to large companies. Before you know it, someone else could run with your idea.” Catherine nods in agreement. “As an inventor, your enthusiasm can be your biggest weakness. You want to tell everyone about your invention. But if you write about it in a newspaper, for example, your idea may already have become unpatentable in Europe. I see it happen time and again.”
Gwen adds one final piece of advice:
“Choose a patent attorney who is a good fit for you and who truly understands the essence of your invention. You won’t always hear what you want to hear, but you will receive the advice you need. That’s crucial, because it ensures that what matters most to your business is properly protected.”